Annual CFO
-$505.97 M
+$16.79 M+3.21%
December 31, 2023
Summary
- As of February 7, 2025, ASND annual cash flow from operations is -$505.97 million, with the most recent change of +$16.79 million (+3.21%) on December 31, 2023.
- During the last 3 years, ASND annual CFO has fallen by -$195.85 million (-63.16%).
- ASND annual CFO is now -6137.67% below its all-time high of $8.38 million, reached on December 31, 2013.
Performance
ASND Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
September 30, 2024
Summary
- ASND quarterly cash flow from operations is not available.
Performance
ASND Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
September 30, 2024
Summary
- ASND TTM cash flow from operations is not available.
Performance
ASND TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ASND Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +3.2% | - | - |
| 3 y3 years | -63.2% | - | - |
| 5 y5 years | -208.7% | - | - |
ASND Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -2.4% | +3.2% | ||||
| 5 y | 5-year | -156.9% | +3.2% | ||||
| alltime | all time | -6137.7% | +3.2% |
Ascendis Pharma A/S Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | -$110.34 M(+154.5%) | -$458.38 M(-9.4%) |
| Dec 2023 | -$505.97 M(-3.2%) | -$43.35 M(-68.0%) | -$505.97 M(-19.5%) |
| Sep 2023 | - | -$135.30 M(-20.1%) | -$628.75 M(+8.7%) |
| Jun 2023 | - | -$169.39 M(+7.3%) | -$578.27 M(+8.3%) |
| Mar 2023 | - | -$157.93 M(-4.9%) | -$533.93 M(+2.1%) |
| Dec 2022 | -$522.76 M(+5.8%) | -$166.14 M(+95.9%) | -$522.76 M(+3.8%) |
| Sep 2022 | - | -$84.81 M(-32.2%) | -$503.74 M(-4.7%) |
| Jun 2022 | - | -$125.05 M(-14.8%) | -$528.76 M(-2.5%) |
| Mar 2022 | - | -$146.76 M(-0.2%) | -$542.56 M(+9.8%) |
| Dec 2021 | -$494.15 M(+59.3%) | -$147.11 M(+33.9%) | -$494.15 M(+11.0%) |
| Sep 2021 | - | -$109.84 M(-20.9%) | -$445.24 M(+8.2%) |
| Jun 2021 | - | -$138.85 M(+41.2%) | -$411.42 M(+22.9%) |
| Mar 2021 | - | -$98.35 M(+0.2%) | -$334.77 M(+7.9%) |
| Dec 2020 | -$310.12 M(+57.5%) | -$98.20 M(+29.2%) | -$310.12 M(+15.7%) |
| Sep 2020 | - | -$76.01 M(+22.2%) | -$267.99 M(+3.9%) |
| Jun 2020 | - | -$62.20 M(-15.6%) | -$257.87 M(+28.0%) |
| Mar 2020 | - | -$73.70 M(+31.4%) | -$201.53 M(+2.3%) |
| Dec 2019 | -$196.96 M(+20.2%) | -$56.08 M(-14.9%) | -$196.96 M(+6.6%) |
| Sep 2019 | - | -$65.89 M(+1024.7%) | -$184.73 M(+8.0%) |
| Jun 2019 | - | -$5.86 M(-91.5%) | -$171.01 M(-9.0%) |
| Mar 2019 | - | -$69.13 M(+57.6%) | -$187.90 M(+14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$163.90 M(+52.2%) | -$43.85 M(-15.9%) | -$163.90 M(+13.5%) |
| Sep 2018 | - | -$52.16 M(+129.3%) | -$144.34 M(+14.7%) |
| Jun 2018 | - | -$22.75 M(-49.6%) | -$125.89 M(-3.3%) |
| Mar 2018 | - | -$45.13 M(+85.7%) | -$130.20 M(+20.9%) |
| Dec 2017 | -$107.70 M(+61.7%) | -$24.30 M(-27.9%) | -$107.70 M(+6.2%) |
| Sep 2017 | - | -$33.71 M(+24.6%) | -$101.43 M(+19.3%) |
| Jun 2017 | - | -$27.06 M(+19.5%) | -$85.04 M(+16.8%) |
| Mar 2017 | - | -$22.64 M(+25.5%) | -$72.82 M(+9.3%) |
| Dec 2016 | -$66.60 M(+38.1%) | -$18.03 M(+4.1%) | -$66.60 M(+11.8%) |
| Sep 2016 | - | -$17.31 M(+16.7%) | -$59.60 M(+6.0%) |
| Jun 2016 | - | -$14.84 M(-9.6%) | -$56.23 M(-0.7%) |
| Mar 2016 | - | -$16.42 M(+48.9%) | -$56.60 M(+17.4%) |
| Dec 2015 | -$48.23 M(+97.1%) | -$11.03 M(-20.9%) | -$48.23 M(+1.7%) |
| Sep 2015 | - | -$13.94 M(-8.4%) | -$47.43 M(+26.0%) |
| Jun 2015 | - | -$15.22 M(+89.0%) | -$37.63 M(+29.5%) |
| Mar 2015 | - | -$8.05 M(-21.3%) | -$29.06 M(+18.7%) |
| Dec 2014 | -$24.47 M(-392.0%) | -$10.23 M(+146.9%) | -$24.47 M(+71.8%) |
| Sep 2014 | - | -$4.14 M(-37.6%) | -$14.25 M(+41.0%) |
| Jun 2014 | - | -$6.64 M(+91.4%) | -$10.11 M(+191.4%) |
| Mar 2014 | - | -$3.47 M | -$3.47 M |
| Dec 2013 | $8.38 M(-1099.8%) | - | - |
| Dec 2012 | -$838.20 K | - | - |
FAQ
- What is Ascendis Pharma A/S annual cash flow from operations?
- What is the all time high annual CFO for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S annual CFO year-on-year change?
- What is the all time high quarterly CFO for Ascendis Pharma A/S?
- What is the all time high TTM CFO for Ascendis Pharma A/S?
What is Ascendis Pharma A/S annual cash flow from operations?
The current annual CFO of ASND is -$505.97 M
What is the all time high annual CFO for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high annual cash flow from operations is $8.38 M
What is Ascendis Pharma A/S annual CFO year-on-year change?
Over the past year, ASND annual cash flow from operations has changed by +$16.79 M (+3.21%)
What is the all time high quarterly CFO for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high quarterly cash flow from operations is -$3.47 M
What is the all time high TTM CFO for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high TTM cash flow from operations is -$3.47 M